
CAS 1159680-21-3
:Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
4 Produkte.
L-Lysine, N6-[[[(2,3-dihydro-2,2,4,6,7-pentamethyl-5-benzofuranyl)sulfonyl]amino]iminomethyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-
CAS:Formel:C35H42N4O7SReinheit:95%Farbe und Form:SolidMolekulargewicht:662.7956Ref: IN-DA000H8A
1g50,00€5g121,00€10g159,00€1kgNachfragen25g501,00€5kgNachfragen100gNachfragen100mg24,00€250mg25,00€Fmoc-HomoArg(Pbf)-OH
CAS:<p>M03211 - Fmoc-HomoArg(Pbf)-OH</p>Formel:C35H46N4O7SReinheit:95%Farbe und Form:SolidMolekulargewicht:666.83Fmoc-L-HomoArg(Pbf)-OH
CAS:Fmoc-L-HomoArg(Pbf)-OHFormel:C35H42N4O7SReinheit:95%Farbe und Form: pale-yellow solidMolekulargewicht:662.80g/molFmoc-Homoarg(Pbf)-OH
CAS:<p>Fmoc-Homoarg(Pbf)-OH is a proteolytic enzyme that belongs to the group of serine proteases. It is used in medicinal chemistry as a potential drug for cardiovascular diseases and other disorders. Fmoc-Homoarg(Pbf)-OH has been shown to have a prolonged plasma half-life, which may be due to the presence of two isoforms with different active sites. The isoform with an active site at the N-terminal end has been shown to have an extended plasma half-life. Fmoc-Homoarg(Pbf)-OH has also been shown to increase blood pressure by inducing vasoconstriction, inhibiting platelet aggregation, and reducing vascular permeability. In addition, it can lead to death by apoptosis or necrosis depending on the severity of injury and duration of reperfusion. This agent also has the potential use in treating ischemia reperfusion injury or cardiovascular disease.</p>Formel:C35H42N4O7SReinheit:(Hplc-Ms) Min. 98 Area-%Molekulargewicht:662.8 g/mol



